PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

• Status: Not yet recruiting
• Trial end date: 2025-04-15

Summary

This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with hydroxychloroquine.

• Phase: Phase 2

Details

• Lead Sponsor: Cancer Trials Ireland
• Collaborator: Novartis
• Treatments: Hydroxychloroquine; Trametinib